Sustaining and expanding behavioral health services by levying an opioid impact fee on opioid manufacturers.
Washington HB 2072 imposes a fee on opioid manufacturers to fund expanded behavioral health and addiction treatment services statewide.
Washington HB 2072 imposes a fee on opioid manufacturers to fund expanded behavioral health and addiction treatment services statewide.
HB 2072 establishes an opioid impact fee on opioid manufacturers in Washington State, with revenues dedicated to expanding and sustaining behavioral health services. The fee targets manufacturers based on opioid sales or distribution volume, creating a dedicated funding stream for treatment and prevention programs.
Behavioral health services—particularly addiction treatment and mental health care—face chronic underfunding and service gaps across Washington. This bill attempts to directly link opioid manufacturers to funding consequences while generating revenue specifically for the communities harmed by the opioid crisis.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.